Treatment Advances

May 06, 2025

The CLIA-venetoclax regimen achieves over 90% response in AML & MDS patients, with high survival rates and low early mortality.

April 25, 2025

Learn how vibecotamab targets CD123 to treat myelodysplastic syndrome, chronic myelomonocytic leukemia, and acute myeloid leukemia.

February 02, 2025

FDA approves Treosulfan (Grafapex) for AML and MDS stem cell transplant conditioning, offering a new alternative to busulfan-based regimens.

December 19, 2024

Learn about cellular therapies recommended for people who have TP53-mutant acute myeloid leukemia and myelodysplastic syndromes.

July 15, 2024

TCR-T Therapies TSC-100 and TSC-101 were given FDA Designation in AML, ALL, and MDS.

June 18, 2024

Cancer vaccines are a promising area of medical research for MDS, aimed at enabling the immune system to target and destroy cancer cells.

June 12, 2024

Imetelstat reduces blood transfusions and improves hemoglobin levels. Learn how this drug works and its safety profile.

May 20, 2024

Dr. Amy DeZern shared how the medicine tamibarotene is helping high-risk MDS and AML patients with an overexpressed RARA gene in their cancer cells.

April 24, 2024

Discover elritercept: Fast Track FDA designation for MDS anemia treatment. Innovative therapy targeting blood cell production pathways.

March 28, 2024

Imetelstat received a positive FDA committee vote for treating transfusion-dependent anemia in LR-MDS. Learn about potential benefits for MDS patients.